(Q36802795)

English

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

scientific article published on 20 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies (English)

1 reference

Europe PubMed Central

16 August 2017

toll-like receptor

0 references

Angela Panoskaltsis-Mortari

5

object named as

Angela Panoskaltsis-Mortari

1 reference

Europe PubMed Central

16 August 2017

7

object named as

Bruce R Blazar

1 reference

Europe PubMed Central

16 August 2017

Sarah R. Cooley

2

object named as

Sarah Cooley

1 reference

Europe PubMed Central

16 August 2017

author name string

Brenda J Weigel

1

1 reference

Europe PubMed Central

16 August 2017

Todd DeFor

3

1 reference

Europe PubMed Central

16 August 2017

Daniel J Weisdorf

4

1 reference

Europe PubMed Central

16 August 2017

Wei Chen

6

1 reference

Europe PubMed Central

16 August 2017

Jeffrey S Miller

8

1 reference

Europe PubMed Central

16 August 2017

publication date

20 June 2012

1 reference

Europe PubMed Central

16 August 2017

American Journal of Hematology

1 reference

Europe PubMed Central

16 August 2017

87

1 reference

Europe PubMed Central

16 August 2017

10

1 reference

Europe PubMed Central

16 August 2017

953-956

1 reference

Europe PubMed Central

16 August 2017

Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Toll-like receptors in the pathogenesis of human disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Inferences, questions and possibilities in Toll-like receptor signalling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

CpG motifs in bacterial DNA and their immune effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

29 September 2017

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

27 June 2018

Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

27 June 2018

Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

5 September 2018

Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

5 September 2018

CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

5 September 2018

Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638918

5 September 2018

Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22718533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential cytokine and Toll-like receptor expression in leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22718533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22718533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.23280

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36802795&oldid=1536788852"